Quality and Patient Safety Articles-Complement inhibitors in treatment of myasthenia gravis

Complement inhibitors in treatment of myasthenia gravis

Pdf Summary

The case describes a woman with refractory anti-AChR–positive generalized myasthenia gravis who is being considered for complement inhibitor therapy (such as eculizumab, ravulizumab, or zilucoplan). Before starting these drugs, the required step is <strong>meningococcal vaccination</strong>.

Complement inhibitors significantly increase the risk of serious, potentially fatal <strong>meningococcal infection</strong> because they block part of the immune system needed to defend against encapsulated bacteria. Therefore, patients must complete vaccination against meningococcus before treatment. This includes both <strong>MenACWY</strong> and <strong>MenB</strong> vaccines. If therapy continues long term, booster doses are needed according to guidelines.

Key points:
- Complement inhibitors are used for <strong>anti-AChR–positive generalized myasthenia gravis</strong>, not anti-MuSK or seronegative MG.
- These medications raise the risk of meningococcal disease by about <strong>1,000–2,000-fold</strong>.
- Vaccination reduces risk but does <strong>not eliminate it</strong>, so ongoing vigilance for infection is still necessary.
- FDA REMS enrollment is recommended for prescribers.

Correct answer: <strong>C. Meningococcal vaccination</strong>.

Keywords

myasthenia gravis

anti-AChR positive

complement inhibitor

eculizumab

ravulizumab

zilucoplan

meningococcal vaccination

MenACWY

MenB

meningococcal infection